Shift From Adalimumab Originator to Biosimilars in Denmark
Thomas Bo Jensen, Seoyoung C. Kim, Espen Jimenez‐Solem, Dorthe Bartels, Hanne Rolighed Christensen, Jón Trærup Andersen
Abstract
The dashed horizontal line represents the Danish patent expiration of the brand-name adalimumab on October 16, 2018. The patent expiration was immediately followed by a shift to biosimilars with a substantial cost reduction.
Topics & Concepts
BiosimilarMedicineAdalimumabCompetition (biology)Market competitionFamily medicinePharmacologyInternal medicineRheumatoid arthritisBiologyEcologyMarket economyEconomicsBiosimilars and Bioanalytical MethodsPharmaceutical Economics and PolicyHealth Systems, Economic Evaluations, Quality of Life